SPPAM
PVLA

Summit Partners Public Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Summit Partners Public Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-389,420
Closed -$40.8M – 212
2025
Q4 		$40.8M Buy
389,420
+354,525
+1,016% +$30.2M 0.85% 43
2025
Q3 		$2.19M Buy
+34,895
New +$1.56M 0.05% 147

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Summit Partners Public Asset Management's PVLA Position: Q1 2026 in Review

Summit Partners Public Asset Management sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 389,420 shares — an estimated $40.8M sold.

Summit Partners Public Asset Management first reported a position in PVLA in Q3 2025 and held it in 2 quarters. The position peaked at $40.8M in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Summit Partners Public Asset Management reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 389,420 Palvella Therapeutics shares in Q1 2026, an estimated $40.8M.
  • Summit Partners Public Asset Management first reported a position in Palvella Therapeutics in Q3 2025 and held it in 2 quarters.
  • Summit Partners Public Asset Management's Palvella Therapeutics position peaked at $40.8M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2026, filed 15 May 2026.